Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biomerica Inc (BMRA)

Biomerica Inc (BMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,953
  • Shares Outstanding, K 16,822
  • Annual Sales, $ 5,340 K
  • Annual Income, $ -7,140 K
  • 60-Month Beta -1.04
  • Price/Sales 2.61
  • Price/Cash Flow N/A
  • Price/Book 1.48
Trade BMRA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.37
  • Most Recent Earnings $-0.11 on 04/12/24
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -439.51%)
  • Historical Volatility 54.78%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,290.73% on 10/09/23
  • IV Low 0.00% on 04/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 100
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 504
  • Open Int (30-Day) 410

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7301 +4.78%
on 04/16/24
1.1900 -35.71%
on 03/20/24
-0.2950 (-27.83%)
since 03/15/24
3-Month
0.7301 +4.78%
on 04/16/24
1.3500 -43.33%
on 02/23/24
-0.1912 (-20.00%)
since 01/16/24
52-Week
0.7040 +8.66%
on 10/05/23
2.1300 -64.08%
on 12/18/23
-0.9140 (-54.44%)
since 04/14/23

Most Recent Stories

More News
Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam

Simple at-home device to increase sensitivity in breast self examsEarly detection of breast cancer saves livesBreast Cancer accounts for 1 in 3 new cases...

BMRA : 0.7550 (-1.95%)
Biomerica to Participate at BTIG Biotech Conference

IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG...

BMRA : 0.7550 (-1.95%)
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...

ACST : 3.30 (-1.79%)
LPTH : 1.4800 (unch)
RCAT : 1.0800 (+13.68%)
IONM : 0.6480 (-0.31%)
PYR : 0.3799 (unch)
OSS : 2.94 (+2.62%)
MODD : 1.5400 (-1.91%)
STRN : 1.3400 (+0.75%)
AEYE : 13.15 (-1.20%)
SMFL : 0.4035 (-1.59%)
LFMD : 9.91 (+3.12%)
SURG : 3.68 (-1.60%)
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™

- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant...

BMRA : 0.7550 (-1.95%)
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population

Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial...

BMRA : 0.7550 (-1.95%)
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021

Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results...

BMRA : 0.7550 (-1.95%)
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when...

BMRA : 0.7550 (-1.95%)
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021

Revenues up 239% over prior year fiscal second quarter  Customer orders backlog of over $4.0 million at November 30, 2021  Walmart began in-store and...

BMRA : 0.7550 (-1.95%)
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million

InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16,...

BMRA : 0.7550 (-1.95%)
Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at HoustonScientific Advisory Board to guide...

BMRA : 0.7550 (-1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

BIOMERICA, INC. is an emerging-growth biotechnology firm that develops, manufactures and distributes medical diagnostic products. The Company is focused on niche products for early detection and monitoring of human diseases and conditions before they become catastrophic and incurable. The customers include...

See More

Key Turning Points

3rd Resistance Point 0.8777
2nd Resistance Point 0.8561
1st Resistance Point 0.8131
Last Price 0.7550
1st Support Level 0.7485
2nd Support Level 0.7269
3rd Support Level 0.6839

See More

52-Week High 2.1300
Fibonacci 61.8% 1.5853
Fibonacci 50% 1.4170
Fibonacci 38.2% 1.2487
Last Price 0.7550
52-Week Low 0.7040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar